<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Daudi) has been grown in the mutant mouse called C.B-17 <z:mp ids='MP_0002536'>SCID</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-eight days after s.c. injection of Daudi cells, a palpable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grew only at the site of injection in <z:hpo ids='HP_0000001'>all</z:hpo> injected mice </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> developed </plain></SENT>
<SENT sid="3" pm="."><plain>Following i.v. inoculation, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were localized in the abdomen, liver, spleen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>The growth pattern and phenotype of the Daudi cells were similar whether the inoculated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells were derived from the in vitro cell line or from in vivo passaged <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The survival time of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing animals was dependent on the dose of i.v.-administered Daudi cells; as few as 100 cells caused <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> mice injected i.v. showed <z:mp ids='MP_0000754'>paresis</z:mp> or <z:hpo ids='HP_0003470'>paralysis</z:hpo> of the hind legs just prior to <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>This was associated with the presence of neoplastic nodules within the spinal canal </plain></SENT>
<SENT sid="8" pm="."><plain>Two surface antigens on Daudi cells (CD19 and CD22) were stably expressed in <z:hpo ids='HP_0000001'>all</z:hpo> the neoplastic lesions </plain></SENT>
<SENT sid="9" pm="."><plain>Radiolabelled anti-CD22 antibodies localized in organs infiltrated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, but did not penetrate primary s.c. <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This model of disseminated vs. <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti-human B-cell antibodies </plain></SENT>
</text></document>